Combination of taxanes with radiation: preclinical studies.
about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerConcurrent chemoradiation for high-risk prostate cancerChemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.Management of high-risk localized prostate cancer.Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer.Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer.ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial.A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy.A Pilot Study of Chemoradiotherapy With Weekly Docetaxel for Thoracic Esophageal Carcinoma With T4 and/or M1 Lymph Node Metastasis.A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer.A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
P2860
Q26766638-D72465B4-274B-4E10-87EF-4BE0DB43F4FDQ26798912-BC648D88-C747-4F10-9F0C-BAF2C878C03DQ33396676-ED7D0D79-3514-4C1A-B7F4-480E1C463951Q35503645-5E1D2030-FC96-4D99-8ED2-AE612B7BE4ABQ35560987-7FF6BD8B-BF47-47FD-A9AF-56BAE3B908D4Q36212799-71628761-D420-4C89-8714-1D323FB4A920Q36886421-2C188F59-DA16-4B8C-BBE1-4C6C482436B7Q37235591-19B2403E-22B5-4E22-9A77-C9375F50C4CAQ37577939-8A1B8B64-0806-474A-B6B7-7DFB08A336D4Q38720703-B2C03D0F-6864-4437-95E8-0D4FA51907F5Q40990593-2570D336-D256-492C-B12B-364F979892B0Q44759597-503063F8-3FFF-48D9-B193-9876699DABD7Q45949842-7A47A74E-5FF5-44A4-B261-7EFB27025AA9Q50321726-EDD8165F-ECEC-4A01-BD52-23D7DDABAF2F
P2860
Combination of taxanes with radiation: preclinical studies.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Combination of taxanes with radiation: preclinical studies.
@ast
Combination of taxanes with radiation: preclinical studies.
@en
type
label
Combination of taxanes with radiation: preclinical studies.
@ast
Combination of taxanes with radiation: preclinical studies.
@en
prefLabel
Combination of taxanes with radiation: preclinical studies.
@ast
Combination of taxanes with radiation: preclinical studies.
@en
P2093
P1476
Combination of taxanes with radiation: preclinical studies.
@en
P2093
P433
P577
1999-04-01T00:00:00Z